Bausch Health Companies Inc. (BHC)

Quarterly Report Filed: 2026-04-30

Key Insights

The filing shows BHC's Q1 2026 financial performance with multiple business segments including Bausch & Lomb operations, indicating continued diversification across pharmaceutical and medical device portfolios.
Notable acquisition activity documented including Whitecap Biosciences, Shibo Zhenmei, DURECT Corporation, and Harmac Medical Products, suggesting an active M&A strategy to expand product pipeline and market presence.
The presence of restructuring and integration costs, along with separation and IPO-related costs in the period, indicates ongoing organizational transformation and potential spin-off or separation activities that could create shareholder value or dilution.
Multiple reserve accounts tracked for discounts, allowances, rebates, chargebacks, and distribution fees demonstrate complex revenue recognition and channel management, which requires careful monitoring for potential margin pressure or customer concentration issues.

Current Report Filed: 2026-04-29

Key Insights

Bausch Health Companies announced Q1 2026 financial results on April 29, 2026, with the press release serving as the primary disclosure vehicle for operational performance and financial metrics.
The filing is a routine quarterly earnings announcement with limited material substance provided in the 8-K itself; substantive financial details are contained in the attached press release (Exhibit 99.1) which is not incorporated by reference and carries no liability under Section 18 of the Securities Exchange Act.
The report was signed by Jean-Jacques Charhon as Executive Vice President and Chief Financial Officer, indicating standard CFO-level certification of the earnings disclosure with no executive leadership changes noted.

Insider Trading Filed: 2026-03-03

Key Insights

Jean-Jacques Charhon, the Executive Vice President and CFO of Bausch Health Companies Inc., disposed of 49,060 common shares on 02/27/2026 to satisfy tax withholding obligations, reducing his direct ownership to 706,478 shares.
The sale appears to be a routine stock disposition to cover tax liabilities and not an unusual or concerning insider transaction.
Investors should monitor any future insider trading activities by Charhon and other key executives for potential signals about the company's financial health or management's confidence in the stock.

Insider Trading Filed: 2026-03-03

Key Insights

The reporting person, Seana Carson, an EVP and General Counsel at Bausch Health Companies Inc. (BHC), has engaged in a series of transactions involving the company's common shares, including share disposals and tax withholding.
Carson has adopted a Rule 10b5-1 trading plan to sell shares, indicating planned and structured insider activity.
The reporting person has also received and disposed of performance share unit awards, which were paid out in cash rather than stock, as previously disclosed by the company.

Insider Trading Filed: 2026-03-03

Key Insights

The reporting person, Thomas Appio, the Chief Executive Officer of Bausch Health Companies Inc. (BHC), has disposed of a significant number of company shares through a combination of share withholding and cash settlement of performance share units.
The share dispositions suggest Appio is reducing his direct ownership stake in the company, potentially for personal or diversification reasons.
The settlement of performance share units in cash rather than stock, as previously reported, indicates a change in the company's equity compensation practices.

Current Report Filed: 2026-03-02

Key Insights

Bausch Health Companies Inc. (BHC) is modifying the settlement terms of certain 2023 performance share unit (PSU) awards, allowing for cash payments instead of stock upon vesting.
The changes affect awards held by two named executive officers, Thomas Appio and Seana Carson, who will receive cash payouts based on the market price of BHC's common stock on the vesting date.
This appears to be an effort by the company to provide liquidity to executives and avoid potential dilution from the settlement of PSU awards in shares.

Insider Trading Filed: 2026-02-27

Key Insights

Jean-Jacques Charhon, the EVP and CFO of Bausch Health Companies Inc., acquired 276,055 common shares of the company through a restricted share unit (RSU) award, increasing his beneficial ownership to 755,538 shares.
Charhon also disposed of 35,977 common shares to satisfy tax withholding obligations upon the vesting of his RSUs, indicating a potential need for liquidity.
The timing of this transaction, occurring in February 2026, suggests the company may be providing equity-based compensation to its executive team, aligning their interests with shareholders.

Insider Trading Filed: 2026-02-27

Key Insights

Steven Hyosig Lee, the SVP, Controller & CAO of Bausch Health Companies Inc., has been granted 45,868 restricted share units (RSUs) that will vest over the next three years.
This insider award indicates the company's commitment to retaining and incentivizing its key executive, which could be positive for investor confidence.
The RSU grant is significant, as it represents a meaningful portion of the executive's current beneficial ownership of 73,239 common shares.

Insider Trading Filed: 2026-02-27

Key Insights

The reporting person, Aimee J. Lenar, was awarded 157,139 restricted share units (RSUs) by Bausch Health Companies Inc. (BHC), indicating the company is providing equity-based compensation to its executives.
Lenar sold 17,578 common shares of BHC, likely to cover tax withholding obligations upon the vesting of the RSUs, suggesting she is actively managing her equity position in the company.
The RSUs granted to Lenar will vest over a three-year period, aligning her interests with long-term shareholders and incentivizing her to drive the company's performance.

Insider Trading Filed: 2026-02-27

Key Insights

The reporting person, Seana Carson, who is the EVP and General Counsel of Bausch Health Companies Inc. (BHC), acquired 212,350 common shares through a restricted share unit (RSU) award on February 25, 2026.
On February 26, 2026, Carson disposed of 32,211 common shares to satisfy tax withholding obligations upon the vesting of the RSUs.
On February 27, 2026, Carson sold 8,388 common shares in the open market pursuant to a Rule 10b5-1 trading plan established on May 7, 2025.

Insider Trading Filed: 2026-02-27

Key Insights

THOMAS APPIO, the Chief Executive Officer of Bausch Health Companies Inc. (BHC), acquired 815,425 common shares through a restricted share unit (RSU) award, increasing his direct ownership to 3,736,536 shares.
APPIO also disposed of 116,502 common shares to satisfy tax withholding obligations upon the vesting of his RSUs, reducing his direct ownership to 3,620,034 shares.
The RSU award and subsequent share disposition suggest APPIO's continued commitment to and confidence in Bausch Health's long-term growth and performance.

Annual Report Filed: 2026-02-19

Key Insights

Bausch Health Companies Inc. (BHC) reported a 5% year-over-year increase in revenue for the 2025 fiscal year, driven by strong performance in its core business segments.
The company's gross margin improved by 200 basis points, indicating improved operational efficiency and pricing power.
BHC provided a positive outlook for 2026, projecting high single-digit revenue growth and margin expansion, which could signal continued momentum for the business.

Current Report Filed: 2026-02-18

Key Insights

Bausch Health Companies Inc. reported its Q4 2025 and full-year 2025 financial results, indicating continued performance with revenue and earnings growth.
The company's press release highlights ongoing business momentum, with specific details on key product lines and operational initiatives.
Investors will likely focus on the company's guidance and outlook for 2026, as well as any notable changes in the business or competitive landscape.

Current Report Filed: 2026-01-23

Key Insights

Bausch Health Companies announced positive results from its global Phase 3 clinical trial evaluating amorphous-rifaximin solid soluble dispersion for the primary prevention of hepatic encephalopathy in adults with liver cirrhosis, a significant milestone for the company.
The successful completion of this trial could lead to regulatory approvals and the potential launch of a new product in Bausch Health's pipeline, which could drive future revenue growth.
Investors should monitor any updates on the regulatory approval process and potential commercial launch of this new treatment, as it could have a meaningful impact on the company's financial performance.

Current Report Filed: 2026-01-13

Key Insights

Bausch Health is providing an update at the JPM Conference on January 14, 2026, including reaffirming its full-year 2025 guidance at the higher end of the range.
The company's management will share strategic and business updates during the presentation, which will be webcast live and available on the Investor Relations section of the company's website.
Bausch Health is cautioning investors that actual results may differ materially from the forward-looking statements due to various risks and uncertainties discussed in its previous filings.

Insider Trading Filed: 2026-01-02

Key Insights

The reporting person, Amy B. Wechsler, acquired 989 common shares of Bausch Health Companies Inc. (BHC) on December 31, 2025, increasing her direct ownership to 266,441 shares.
The shares were acquired as restricted share units issued in lieu of cash compensation for the reporting person's service on the company's Board of Directors for the quarter ending December 31, 2025.
This transaction indicates the reporting person's continued involvement and confidence in the company's leadership and future prospects.

Current Report Filed: 2026-01-02

Key Insights

Bausch + Lomb has refinanced its outstanding term loans, extending the maturity date to 2031 and reducing the applicable interest rate margins.
The refinancing provides Bausch + Lomb with improved financial flexibility and potentially lower borrowing costs going forward.
The press release indicates the refinancing was successfully completed, which should be viewed positively by investors.

Insider Trading Filed: 2026-01-02

Key Insights

John Paulson, a director of Bausch Health Companies Inc. (BHC), acquired 8,992 common shares through restricted share units issued as part of his board compensation on 12/31/2025.
Paulson's total direct ownership in BHC increased to 360,120 common shares, while he also holds an indirect beneficial ownership of 73,255,869 shares through managed funds.
The insider buying activity suggests Paulson's confidence in the company's prospects, as he increases his personal stake in BHC.

Insider Trading Filed: 2026-01-02

Key Insights

The reporting person, Sandra Leung, acquired 4,586 common shares of Bausch Health Companies Inc. (BHC) on 12/31/2025, increasing her direct beneficial ownership to 38,408 shares.
The shares acquired were granted as restricted share units in lieu of cash compensation for her service on the company's board of directors.
This insider transaction indicates ongoing engagement and confidence in the company by a member of the board of directors.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information